239 related articles for article (PubMed ID: 11734733)
1. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience.
Neuzil KM; Dupont WD; Wright PF; Edwards KM
Pediatr Infect Dis J; 2001 Aug; 20(8):733-40. PubMed ID: 11734733
[TBL] [Abstract][Full Text] [Related]
2. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease.
Edwards KM; Dupont WD; Westrich MK; Plummer WD; Palmer PS; Wright PF
J Infect Dis; 1994 Jan; 169(1):68-76. PubMed ID: 8277200
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of inactivated influenza virus vaccine in young children in 2003-2004.
Mitchell DK; Ruben FL; Gravenstein S
Pediatr Infect Dis J; 2005 Oct; 24(10):925-7. PubMed ID: 16220095
[TBL] [Abstract][Full Text] [Related]
4. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children.
Zangwill KM; Droge J; Mendelman P; Marcy SM; Partridge S; Chiu CY; Jing J; Chang SJ; Cho I; Ward JI
Pediatr Infect Dis J; 2001 Aug; 20(8):740-6. PubMed ID: 11734734
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM
J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B.
Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M
JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-blind, Active-controlled Clinical Trial of a Cell Culture-derived Inactivated Trivalent Influenza Vaccine (NBP607) in Healthy Children 6 Months Through 18 Years of Age.
Oh CE; Choi UY; Eun BW; Lee TJ; Kim KH; Kim DH; Kim NH; Jo DS; Shin SH; Kim KH; Kim H; Kim YK
Pediatr Infect Dis J; 2018 Jun; 37(6):605-611. PubMed ID: 29528914
[TBL] [Abstract][Full Text] [Related]
9. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren.
Khan AS; Polezhaev F; Vasiljeva R; Drinevsky V; Buffington J; Gary H; Sominina A; Keitel W; Regnery H; Lonskaya NL; Doroshenko E; Gavrilov A; Ivakhov I; Arden N; Schonberger LB; Couch R; Kendal A; Cox N
J Infect Dis; 1996 Feb; 173(2):453-6. PubMed ID: 8568310
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
Fleming DM; Crovari P; Wahn U; Klemola T; Schlesinger Y; Langussis A; Øymar K; Garcia ML; Krygier A; Costa H; Heininger U; Pregaldien JL; Cheng SM; Skinner J; Razmpour A; Saville M; Gruber WC; Forrest B;
Pediatr Infect Dis J; 2006 Oct; 25(10):860-9. PubMed ID: 17006278
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
[TBL] [Abstract][Full Text] [Related]
12. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
13. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB; Nolan T; Borja-Tabora CF; Santos J; Montalban MC; de Looze FJ; Eizenberg P; Hall S; Dupuy M; Hutagalung Y; Pépin S; Saville M
Vaccine; 2015 May; 33(21):2485-92. PubMed ID: 25843270
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
Langley JM; Carmona Martinez A; Chatterjee A; Halperin SA; McNeil S; Reisinger KS; Aggarwal N; Huang LM; Peng CT; Garcia-Sicilia J; Salamanca de la Cueva I; Cabañas F; Treviño-Garza C; Rodríguez-Weber MA; de la O M; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
J Infect Dis; 2013 Aug; 208(4):544-53. PubMed ID: 23847058
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and immunogenicity of influenza vaccine in HIV-infected children: a randomized, double-blind, placebo controlled trial.
Madhi SA; Dittmer S; Kuwanda L; Venter M; Cassim H; Lazarus E; Thomas T; Liberty A; Treurnich F; Cutland CL; Weinberg A; Violari A
AIDS; 2013 Jan; 27(3):369-79. PubMed ID: 23032417
[TBL] [Abstract][Full Text] [Related]
17. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50-64 years of age.
DiazGranados CA; Saway W; Gouaux J; Baron M; Baker J; Denis M; Jordanov E; Landolfi V; Yau E
Vaccine; 2015 Dec; 33(51):7188-7193. PubMed ID: 26555348
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial to compare the safety and immunogenicity of CSL Limited's 2009 trivalent inactivated influenza vaccine to an established vaccine in United States children.
Brady RC; Hu W; Houchin VG; Eder FS; Jackson KC; Hartel GF; Sawlwin DC; Albano FR; Greenberg M
Vaccine; 2014 Dec; 32(52):7141-7. PubMed ID: 25454878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
